Age-dependent shift in the de novo proteome accompanies pathogenesis in an Alzheimer’s disease mouse model

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder associated with memory loss, but the AD-associated neuropathological changes begin years before memory impairments. Investigation of the early molecular abnormalities in AD might offer innovative opportunities to target memory impairment prior to onset. Decreased protein synthesis plays a fundamental role in AD, yet the consequences of this dysregulation for cellular function remain unknown. We hypothesize that alterations in the de novo proteome drive early metabolic alterations in the hippocampus that persist throughout AD progression. Using a combinatorial amino acid tagging approach to selectively label and enrich newly synthesized proteins, we found that the de novo proteome is disturbed in young APP/PS1 mice prior to symptom onset, affecting the synthesis of multiple components of the synaptic, lysosomal, and mitochondrial pathways. Furthermore, the synthesis of large clusters of ribosomal subunits were affected throughout development. Our data suggest that large-scale changes in protein synthesis could underlie cellular dysfunction in AD. Elder et al. investigated the de novo proteome in isolated hippocampal slices of young APP/PS1 Alzheimer’s model mice and revealed that large-scale changes in protein synthesis precede symptom onset. These results suggest that broad dysregulation of protein synthesis could contribute toward cellular dysfunction in Alzheimer’s disease.

[1]  E. Nollen,et al.  Regulation of Age-Related Protein Toxicity , 2021, Frontiers in Cell and Developmental Biology.

[2]  E. Klann,et al.  Dysregulation of the de novo proteome accompanies pathology progression in the APP/PS1 mouse model of Alzheimer’s disease , 2020, bioRxiv.

[3]  S. Birman,et al.  Hedgehog Signaling Modulates Glial Proteostasis and Lifespan. , 2020, Cell reports.

[4]  Daniel B. McClatchy,et al.  A Temporal Quantitative Profiling of Newly Synthesized Proteins during Aβ Accumulation , 2020, bioRxiv.

[5]  Li Luo,et al.  Studies on APP metabolism related to age-associated mitochondrial dysfunction in APP/PS1 transgenic mice , 2019, Aging.

[6]  Gary D. Bader,et al.  Single-cell transcriptomic profiling of the aging mouse brain , 2019, Nature Neuroscience.

[7]  C. Holt,et al.  Local translation in neurons: visualization and function , 2019, Nature Structural & Molecular Biology.

[8]  S. Carr,et al.  TMT Labeling for the Masses: A Robust and Cost-efficient, In-solution Labeling Approach. , 2019, Molecular & cellular proteomics : MCP.

[9]  L. Bodea,et al.  Decreased synthesis of ribosomal proteins in tauopathy revealed by non‐canonical amino acid labelling , 2019, The EMBO journal.

[10]  E. Klann,et al.  Altered steady state and activity-dependent de novo protein expression in fragile X syndrome , 2019, Nature Communications.

[11]  C. Keene,et al.  Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer’s disease model mice , 2019, The Journal of clinical investigation.

[12]  A. Grimm,et al.  Link between the unfolded protein response and dysregulation of mitochondrial bioenergetics in Alzheimer’s disease , 2019, Cellular and Molecular Life Sciences.

[13]  C. Holt,et al.  On-Site Ribosome Remodeling by Locally Synthesized Ribosomal Proteins in Axons , 2018, bioRxiv.

[14]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[15]  Kathryn Goozee,et al.  Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies , 2018, Journal of Alzheimer's disease : JAD.

[16]  Mitesh Patel,et al.  ZCCHC17 is a master regulator of synaptic gene expression in Alzheimer's disease , 2018, Bioinform..

[17]  R. Swerdlow Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[18]  K. Fujii,et al.  Heterogeneous Ribosomes Preferentially Translate Distinct Subpools of mRNAs Genome-wide. , 2017, Molecular cell.

[19]  R. Nixon Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  José Cristóbal Riquelme Santos,et al.  Machine learning techniques to discover genes with potential prognosis role in Alzheimer's disease using different biological sources , 2017, Inf. Fusion.

[21]  J. Lucas,et al.  Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome , 2016, Brain pathology.

[22]  C. Vogel,et al.  BONLAC: A combinatorial proteomic technique to measure stimulus-induced translational profiles in brain slices , 2016, Neuropharmacology.

[23]  E. Klann,et al.  Mitochondrial Superoxide Contributes to Hippocampal Synaptic Dysfunction and Memory Deficits in Angelman Syndrome Model Mice , 2015, The Journal of Neuroscience.

[24]  A. Cuervo,et al.  Proteostasis and aging , 2015, Nature Network Boston.

[25]  U. Pati,et al.  CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of β-secretase , 2015, Aging cell.

[26]  Yong Tae Kwon,et al.  Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies , 2015, Experimental & Molecular Medicine.

[27]  L. Ji,et al.  Exercise-Induced Neuroprotection of Hippocampus in APP/PS1 Transgenic Mice via Upregulation of Mitochondrial 8-Oxoguanine DNA Glycosylase , 2014, Oxidative medicine and cellular longevity.

[28]  Guoan Zhang,et al.  In-Depth Quantitative Proteomic Analysis of de Novo Protein Synthesis Induced by Brain-Derived Neurotrophic Factor , 2014, Journal of proteome research.

[29]  Wei Huang,et al.  Translational control in synaptic plasticity and cognitive dysfunction. , 2014, Annual review of neuroscience.

[30]  E. Airoldi,et al.  Differential Stoichiometry among Core Ribosomal Proteins , 2014, bioRxiv.

[31]  M. Frosch,et al.  Tracking the earliest pathologic changes in Alzheimer disease , 2014, Neurology.

[32]  W. Gan,et al.  Antipsychotics Activate mTORC1-Dependent Translation to Enhance Neuronal Morphological Complexity , 2014, Science Signaling.

[33]  D. Munoz,et al.  TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. , 2013, Cell metabolism.

[34]  G. Hu,et al.  Aerobic Exercise Combined with Antioxidative Treatment does not Counteract Moderate‐ or Mid‐Stage Alzheimer‐Like Pathophysiology of APP/PS1 Mice , 2013, CNS neuroscience & therapeutics.

[35]  E. Klann,et al.  Genetic reduction of the α1 subunit of Na/K-ATPase corrects multiple hippocampal phenotypes in Angelman syndrome. , 2013, Cell reports.

[36]  E. Klann,et al.  Suppression of eIF2α kinases alleviates AD-related synaptic plasticity and spatial memory deficits , 2013, Nature Neuroscience.

[37]  J. DeFelipe,et al.  Synaptic Changes in the Dentate Gyrus of APP/PS1 Transgenic Mice Revealed by Electron Microscopy , 2013, Journal of neuropathology and experimental neurology.

[38]  F. Ebner,et al.  In vivo quantitative proteomics of somatosensory cortical synapses shows which protein levels are modulated by sensory deprivation , 2013, Proceedings of the National Academy of Sciences.

[39]  Katrin Eichelbaum,et al.  Selective enrichment of newly synthesized proteins for quantitative secretome analysis , 2012, Nature Biotechnology.

[40]  Michael J. Sweredoski,et al.  Dopaminergic modulation of the hippocampal neuropil proteome identified by bioorthogonal noncanonical amino acid tagging (BONCAT) , 2012, Proteomics.

[41]  Heng Du,et al.  Synaptic mitochondrial pathology in Alzheimer's disease. , 2012, Antioxidants & redox signaling.

[42]  E. Klann,et al.  Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the ΔRG mouse model of tuberous sclerosis complex , 2012, Neurobiology of Disease.

[43]  I. Willis,et al.  Eukaryotic Cells Producing Ribosomes Deficient in Rpl1 Are Hypersensitive to Defects in the Ubiquitin-Proteasome System , 2011, PloS one.

[44]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[45]  Jerry Yang,et al.  Inhibitors of Catalase-Amyloid Interactions Protect Cells from β-Amyloid-Induced Oxidative Stress and Toxicity* , 2010, The Journal of Biological Chemistry.

[46]  M. Jensen,et al.  Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1ΔE9-deleted transgenic mice model of β-amyloidosis , 2010, Neurobiology of Aging.

[47]  C. Hölscher,et al.  Synaptic Plasticity in the Hippocampus of a APP/PS1 Mouse Model of Alzheimer's Disease Is Impaired in Old but Not Young Mice , 2010, PloS one.

[48]  E. Klann,et al.  Dysregulation of mTOR Signaling in Fragile X Syndrome , 2010, The Journal of Neuroscience.

[49]  M. Jendrach,et al.  Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice , 2009, Neurobiology of Aging.

[50]  O. Arancio,et al.  Reversal of long-term dendritic spine alterations in Alzheimer disease models , 2009, Proceedings of the National Academy of Sciences.

[51]  R. D'Hooge,et al.  γ-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer’s Disease , 2009, Science.

[52]  Sylvain Rheims,et al.  Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy , 2009, The Journal of Neuroscience.

[53]  Qingzhong Liu,et al.  Independent component analysis of Alzheimer's DNA microarray gene expression data , 2009, Molecular Neurodegeneration.

[54]  N. Sonenberg,et al.  Translational Control of Long-Lasting Synaptic Plasticity and Memory , 2009, Neuron.

[55]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[56]  A. Gruart,et al.  Aged wild-type and APP, PS1, and APP+PS1 mice present similar deficits in associative learning and synaptic plasticity independent of amyloid load , 2008, Neurobiology of Disease.

[57]  Costel C. Darie,et al.  Stable Isotopic Labeling by Amino Acids in Cultured Primary Neurons , 2008, Molecular & Cellular Proteomics.

[58]  J. Glennon,et al.  Age‐related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild‐type mice , 2008, Journal of neurochemistry.

[59]  P. Moreira,et al.  Alzheimer's disease: a lesson from mitochondrial dysfunction. , 2007, Antioxidants & redox signaling.

[60]  N. Harel,et al.  Subcutaneous Nogo Receptor Removes Brain Amyloid-β and Improves Spatial Memory in Alzheimer's Transgenic Mice , 2006, The Journal of Neuroscience.

[61]  Hartwig Wolburg,et al.  Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.

[62]  Daniela C Dieterich,et al.  Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Markesbery,et al.  Ribosome Dysfunction Is an Early Event in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[64]  R. Ravid,et al.  Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice* , 2005, Journal of Biological Chemistry.

[65]  Ottavio Arancio,et al.  Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. , 2005, Current Alzheimer research.

[66]  B. Winblad,et al.  Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain , 2004, Neuroreport.

[67]  Ottavio Arancio,et al.  Progressive age‐related development of Alzheimer‐like pathology in APP/PS1 mice , 2004, Annals of neurology.

[68]  Wei-Lun Chang,et al.  Molecular characterization of a novel nucleolar protein, pNO40. , 2003, Biochemical and biophysical research communications.

[69]  H. Braak,et al.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. , 2003, The American journal of pathology.

[70]  R. Chang,et al.  Phosphorylation of eukaryotic initiation factor-2&agr; (eIF2&agr;) is associated with neuronal degeneration in Alzheimer's disease , 2002, Neuroreport.

[71]  I. Ferrer Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt–Jakob's disease , 2002, Neuropathology and applied neurobiology.

[72]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[73]  Nick C Fox,et al.  Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[74]  N. Kenmochi,et al.  The human ribosomal protein genes: sequencing and comparative analysis of 73 genes. , 2002, Genome research.

[75]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[76]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[77]  A. Nunomura,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[78]  H. Hamazaki Cathepsin D is involved in the clearance of Alzheimer's β‐amyloid protein , 1996 .

[79]  S. Ng,et al.  Aberrant GAP-43 gene expression in Alzheimer's disease. , 1995, The American journal of pathology.

[80]  Jinhe Li,et al.  Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system , 1995, Neuron.

[81]  B. Winblad,et al.  Alzheimer's disease-associated reduction of polysomal mRNA translation. , 1989, Brain research. Molecular brain research.

[82]  C. Marotta,et al.  Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. , 1984, Science.

[83]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[84]  W. Markesbery,et al.  Neuropathologic alterations in mild cognitive impairment: a review. , 2010, Journal of Alzheimer's disease : JAD.

[85]  E. Klann,et al.  Making synaptic plasticity and memory last: mechanisms of translational regulation. , 2009, Genes & development.

[86]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[87]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[88]  Stavros J. Baloyannis,et al.  Mitochondrial alterations in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[89]  K. Blennow,et al.  Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study , 2000, Journal of Neural Transmission.

[90]  A. Alzheimer Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .